Consistent with the results, we showed that a NANOGhigh tumor with CTL-refractory property exhibited resistance to trastuzumab-mediated CDC, whereas silencing of NANOG led to increase in susceptibility of trastuzumab-mediated CDC. This evidence concerns the gene NANOG and neoplasm.